Dysentery, Amebic

Main study objectives To investigate the pharmacokinetic characteristics of a single oral tablet of ornidazole tablets (test preparation T, specification: 0.5g) produced by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. and a single oral tablet of ornidazole tablets (reference preparation R, trade name: Tiberal®, specification: 0.5g) certified by OrPha Swiss GmbH under the same conditions in healthy subjects under fasting and postprandial conditions, evaluate the bioequivalence of the two preparations, and provide a basis for the consistency evaluation of the test preparation. Secondary study objectives To observe the safety of a single oral administration of 0.5g of the test preparation ornidazole tablets (specification: 0.5g) and the reference preparation ornidazole tablets (trade name: Tiberal®, specification: 0.5g) in healthy subjects under fasting and postprandial conditions.